# US 2022/0033906 A1 · Mirnas as biomarkers for parkinson's syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033906 A1
- Document ID: US20220033906A1
- Status: Published application
- Kind: A1
- Application number: 17/413,173
- Filed: 2019-12-18
- Published: 2022-02-03
- Earliest claimed: 2018-12-18
- Assignees: Hummingbird Diagnostics GmbH
- Applicants: Hummingbird Diagnostics GmbH
- Inventors: Andreas Keller; Bruno Steinkraus
- Web page: https://patentgrep.com/patent/US20220033906A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for diagnosing a Parkinson's syndrome (PS), Parkinson's disease (PD), or Parkinsonism in an individual. Further, the present invention relates to a method for differential diagnosing between PD and Parkinsonism. Furthermore, the present invention relates to methods for monitoring the course of a Parkinson's syndrome, Parkinson's disease (PD), or Parkinsonism in an individual. In addition, the present invention relates to kits suitable to carry out the above described methods.

## Claims

### Claim at position 1

-70. (canceled)

### Claim 71

A method for
(a) diagnosing a Parkinson's syndrome (PS) in an individual (suspected of having a Parkinson's syndrome), or
(b) determining the course of a Parkinson's syndrome in an individual having a Parkinson's syndrome
comprising the step of:
determining the level of at least one miRNA in a biological sample isolated from the individual (suspected of having a Parkinson's syndrome),
wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 23, and a sequence having at least 90% sequence identity thereto.

### Claim 72 (depends on 71)

The method of claim 71 (a), wherein the level of the at least one miRNA is compared to a reference level of said at least one miRNA, and wherein the reference level is the level determined by measuring at least one reference biological sample isolated from at least one subject not suffering from a Parkinson's syndrome (being healthy).

### Claim 73 (depends on 72)

The method of claim 72, wherein
(i) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, and a sequence having at least 90% sequence identity thereto above the reference level indicates that the individual has a Parkinson's syndrome, and/or
(ii) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 16, SEQ ID NO: 22, and a sequence having at least 90% sequence identity thereto below the reference level indicates that the individual has a Parkinson's syndrome.

### Claim 74 (depends on 71)

The method of claim 71 (b), wherein said determining comprises determining the level of the at least one miRNA in a biological sample at a first point in time and in at least one further biological sample at a later point in time and comparing said levels determined at the different time points.

### Claim 75 (depends on 74)

The method of claim 74, wherein
(i) the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, and a sequence having at least 90% sequence identity and wherein the level of said at least one miRNA which
(a) increases over time indicates that the Parkinson's syndrome worsens in the individual,
(b) does not change over time indicates that the Parkinson's syndrome does not worsen/is stable in the individual, or
(c) decreases over time indicates that the Parkinson's syndrome improves in the individual,
and/or
(ii) the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 16, SEQ ID NO: 22, and a sequence having at least 90% sequence identity thereto and wherein the level of said at least one miRNA which
(a) decreases over time indicates that the Parkinson's syndrome worsens in the individual,
(b) does not change over time indicates that the Parkinson's syndrome does not worsen/is stable in the individual, or
(c) increases over time indicates that the Parkinson's syndrome improves in the individual.

### Claim 76

A method for
(a) diagnosing Parkinson's disease (PD) in an individual (suspected of having PD), or
(b) determining the course of Parkinson's disease (PD) in an individual having PD comprising the step of:
determining the level of at least one miRNA in a biological sample isolated from the individual (suspected of having PD),
wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 7 to SEQ ID NO: 13, SEQ ID NO: 16 to SEQ ID NO: 23, SEQ ID NO: 47 to SEQ ID NO: 59, and a sequence having at least 90% sequence identity thereto.

### Claim 77 (depends on 76)

The method of claim 76 (a), wherein the level of the at least one miRNA is compared to a reference level of said at least one miRNA, and wherein the reference level is the level determined by measuring at least one reference biological sample isolated from at least one subject not suffering from PD (being healthy).

### Claim 78 (depends on 77)

The method of claim 77, wherein
(i) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 5, SEQ ID NO: 7 to SEQ ID NO: 13, SEQ ID NO: 17 to SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 48 to SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 59, and a sequence having at least 90% sequence identity thereto above the reference level indicates that the individual has PD, and/or
(ii) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 16, SEQ ID NO: 22, SEQ ID NO: 47, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 57, and a sequence having at least 90% sequence identity thereto below the reference level indicates that the individual has PD.

### Claim 79 (depends on 76)

The method of claim 76 (b), wherein said determining comprises determining the level of the at least one miRNA in a biological sample at a first point in time and in at least one further biological sample at a later point in time and comparing said levels determined at the different time points.

### Claim 80 (depends on 79)

The method of claim 79, wherein
(i) the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 5, SEQ ID NO: 7 to SEQ ID NO: 13, SEQ ID NO: 17 to SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 48 to SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 59, and a sequence having at least 90% sequence identity thereto and wherein the level of said at least one miRNA which
(a) increases over time indicates that PD worsens in the individual,
(b) does not change over time indicates that PD does not worsen/is stable in the individual, or
(c) decreases over time indicates that PD improves in the individual,
and/or
(ii) the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 16, SEQ ID NO: 22, SEQ ID NO: 47, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 57, and a sequence having at least 90% sequence identity thereto and wherein the level of said at least one miRNA which
(a) decreases over time indicates that PD worsens in the individual,
(b) does not change over time indicates that PD does not worsen/is stable in the individual, or
(c) increases over time indicates that PD improves in the individual.

### Claim 81

A method for
(a) diagnosing Parkinsonism in an individual (suspected of having Parkinsonism), or
(b) determining the course of Parkinsonism in an individual having Parkinsonism comprising the step of:
determining the level of at least one miRNA in a biological sample isolated from the individual (suspected of having Parkinsonism),
wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 8 to SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19 to SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 41 to SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 56, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 68, SEQ ID NO: 72, SEQ ID NO: 74 to SEQ ID NO: 96, SEQ ID NO: 107, and a sequence having at least 90% sequence identity thereto.

### Claim 82 (depends on 81)

The method of claim 81 (a), wherein the level of the at least one miRNA is compared to a reference level of said at least one miRNA, and wherein the reference level is the level determined by measuring at least one reference biological sample isolated from at least one subject not suffering from Parkinsonism (being healthy).

### Claim 83 (depends on 82)

The method of claim 82, wherein
(i) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 5, SEQ ID NO: 8 to SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 27, SEQ ID NO: 41 to SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 56, SEQ ID NO: 68, SEQ ID NO: 72, SEQ ID NO: 74 to SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 83, SEQ ID NO: 88 to SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 96, and a sequence having at least 90% sequence identity thereto above the reference level indicates that the individual has Parkinsonism, and/or
(ii) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 77, SEQ ID NO: 80 to SEQ ID NO: 82, SEQ ID NO: 84 to SEQ ID NO: 87, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 107, and a sequence having at least 90% sequence identity thereto below the reference level indicates that the individual has Parkinsonism.

### Claim 84 (depends on 81)

The method of claim 81 (b), wherein said determining comprises determining the level of the at least one miRNA in a biological sample at a first point in time and in at least one further biological sample at a later point in time and comparing said levels determined at the different time points.

### Claim 85 (depends on 84)

The method of claim 84, wherein
(i) the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 5, SEQ ID NO: 8 to SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 27, SEQ ID NO: 41 to SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 56, SEQ ID NO: 68, SEQ ID NO: 72, SEQ ID NO: 74 to SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 83, SEQ ID NO: 88 to SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 96, and a sequence having at least 90% sequence identity thereto and wherein the level of said at least one miRNA which
(a) increases over time indicates that the Parkinsonism worsens in the individual,
(b) does not change over time indicates that the Parkinsonism does not worsen/is stable in the individual, or
(c) decreases over time indicates that the Parkinsonism improves in the individual,
and/or
(ii) the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 77, SEQ ID NO: 80 to SEQ ID NO: 82, SEQ ID NO: 84 to SEQ ID NO: 87, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 107, and a sequence having at least 90% sequence identity thereto and wherein the level of said at least one miRNA which
(a) decreases over time indicates that the Parkinsonism worsens in the individual,
(b) does not change over time indicates that the Parkinsonism does not worsen/is stable in the individual, or
(c) increases over time indicates that the Parkinsonism improves in the individual.

### Claim 86

A method for differentiating between Parkinson's disease (PD) and Parkinsonism comprising the step of:
determining the level of at least one miRNA in a biological sample isolated from an individual (having a Parkinson's syndrome),
wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 17, SEQ ID NO: 37, SEQ ID NO: 42, SEQ ID NO: 45, SEQ ID NO: 60, SEQ ID NO: 70, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 84, SEQ ID NO: 88, SEQ ID NO: 93, SEQ ID NO: 97 to SEQ ID NO: 106, and a sequence having at least 90% sequence identity thereto.

### Claim 87 (depends on 86)

The method of claim 86, wherein the level of the at least one miRNA is compared to a reference level of said at least one miRNA.

### Claim 88 (depends on 87)

The method of claim 87, wherein the reference level is the level determined by measuring at least one reference biological sample isolated from at least one subject suffering from Parkinsonism, and wherein
(i) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 45, SEQ ID NO: 70, SEQ ID NO: 77, SEQ ID NO: 84, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, and a sequence having at least 90% sequence identity thereto above the reference level indicates that the individual has PD, and/or
(ii) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 42, SEQ ID NO: 76, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, and a sequence having at least 90% sequence identity thereto below the reference level indicates that the individual has PD.

### Claim 89 (depends on 87)

The method of claim 87, wherein the reference level is the level determined by measuring at least one reference biological sample isolated from at least one subject suffering from PD, and wherein
(i) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 37, SEQ ID NO: 45, SEQ ID NO: 70, SEQ ID NO: 77, SEQ ID NO: 84, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, and a sequence having at least 90% sequence identity thereto below the reference level indicates that the individual has Parkinsonism, and/or
(ii) the level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 42, SEQ ID NO: 76, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, and a sequence having at least 90% sequence identity thereto above the reference level indicates that the individual has Parkinsonism.
